Novartis
NVS
1,178 hedge funds and large institutions have $15.5B invested in Novartis in 2022 Q4 according to their latest regulatory filings, with 117 funds opening new positions, 293 increasing their positions, 497 reducing their positions, and 59 closing their positions.
134% more call options, than puts
Call options by funds: $798M | Put options by funds: $341M
98% more first-time investments, than exits
New positions opened: 117 | Existing positions closed: 59
30% more funds holding in top 10
Funds holding in top 10: 10 → 13 (+3)
9% more funds holding
Funds holding: 1,084 → 1,178 (+94)
0.27% less ownership
Funds ownership: 8.22% → 7.95% (-0.27%)
41% less repeat investments, than reductions
Existing positions increased: 293 | Existing positions reduced: 497
59% less capital inflows, than outflows
Capital inflows: $574M | Capital outflows: $1.39B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$210M |
| 2 |
MUFG Securities EMEA
London,
United Kingdom
|
+$50.5M |
| 3 |
Janus Henderson Group
London,
|
+$50M |
| 4 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$46.8M |
| 5 |
Renaissance Technologies
New York
|
+$20.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$336M |
| 2 |
Boston Partners
Boston,
Massachusetts
|
-$147M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$71.4M |
| 4 |
Goldman Sachs
New York
|
-$68.1M |
| 5 |
Two Sigma Advisers
New York
|
-$61.4M |
NVS Hedge Fund Activity: Q4 2022 in Review
1,178 of the 6,238 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q4 2022, worth a combined $15.5B — up 13% from $13.6B a quarter earlier.
Buyers outnumbered sellers: 117 funds opened new NVS positions and 59 closed out — a net gain of 58 holders — while 293 added to existing stakes and 497 trimmed.
The largest buyer was Arrowstreet Capital, adding an estimated $210M. The largest seller was Loomis, Sayles & Company, cutting an estimated $336M.
- 1,178 institutional investors held Novartis (NVS) as of Q4 2022, up from 1,084 in Q3 2022.
- Funds reported $15.5B of Novartis stock for Q4 2022, up 13% quarter-over-quarter.
- 117 funds opened new Novartis positions in Q4 2022 and 59 closed out, a net change of +58 holders.
- The largest Novartis buyer in Q4 2022 was Arrowstreet Capital, an estimated $210M added.
- The largest Novartis seller in Q4 2022 was Loomis, Sayles & Company, an estimated $336M sold.
Based on aggregated 13F filings for Q4 2022.